Fenebrutinib Shows Promise in MS Trial Results
Update: 2025-11-10
Description
Roches experimental MS pill, fenebrutinib, shows promising results in late-stage trials, reducing relapses and slowing disability progression in both relapsing and primary progressive MS. The drug outperformed teriflunomide and held its ground against OCREVUS, Roches approved therapy. Roche shares surged, and the company plans to submit all data for regulatory approval in the first half of 2026.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
